![Patrick Volkert Vink](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrick Volkert Vink
Ordförande på
ARCH BIOPARTNERS INC.
Förmögenhet: 265 267 $ per 2026-06-30
Profil
Patrick Volkert Vink currently works at Arch Biopartners, Inc., as Chairman from 2026, F2G Ltd., as Chairman from 2019, BiognoSYS AG, as Chairman from 2020, Targovax Oy, as Chairman, Essential Pharmaceuticals LLC, as Chairman, Avacta Group Plc, as Deputy Chairman from 2026, Secura Bio, Inc., as Chairman, SQZ Biotechnologies Co., as Independent Director from 2021, Spero Therapeutics, Inc., as Lead Independent Director from 2023, F2g Inc., as Director, Forbion Capital Partners Management Holding BV, as Venture Partner, and Gyrus Capital SA, as Advisory Partner from 2020.
Dr. Vink also formerly worked at Micreos BV, as Chairman, Acacia Pharma Ltd., as Non-Executive Chairman from 2016 to 2020, Circio Holding ASA, as Chairman from 2017 to 2020, PIQUR Therapeutics AG, as Chairman, Acacia Pharma Group Ltd., as Non-Executive Chairman from 2016 to 2020, NMD Pharma A, as Chairman from 2015 to 2023, Essential Pharmaceuticals Ltd., as Chairman, Amryt Pharma Holdings Ltd., as Non-Executive Director from 2019 to 2023, Amryt Pharma PLC, as Non Executive Director from 2019 to 2023, Arch Biopartners, Inc., as Non-Executive Director from 2016 to 2019, Santhera Pharmaceuticals Holding AG, as Independent Director from 2017 to 2023, Inhibikase Therapeutics, Inc., as Director, Advanz Pharma Corp.
Ltd., as Independent Non-Executive Director from 2016 to 2018, Biogen, Inc., as Vice President-International Business from 2000 to 2002, Cubist Pharmaceuticals LLC, as Chief Operating Officer & Executive Vice President in 2015, Sandoz, Inc., as Head-Business Franchise Biopharmaceuticals from 2002 to 2006, Mylan, Inc., as SVP, Global Head-Hospital Business & Biologics from 2008 to 2012, Sanofi-Synthelabo, Inc., as Head-Worldwide Marketing from 1997 to 2000, and Novartis Sandoz Thailand Ltd, as Head-Global Business Franchise Biopharmaceuticals.
Dr. Vink received his doctorate degree in 1988 from the University of Leiden and Masters Business Admin degree in 1992 from the University of Rochester.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
SPERO THERAPEUTICS, INC. 0,13 % | 2026-06-23 | 75 000 ( 0,13 % ) | 165 750 $ | 2026-06-30 |
ARCH BIOPARTNERS, INC. 0,27 % | 2026-01-15 | 181 600 ( 0,27 % ) | 99 517 $ | 2026-06-30 |
Aktiva positioner av Patrick Volkert Vink
| Företag | Position | Start |
|---|---|---|
| SPERO THERAPEUTICS, INC. | Direktör/Styrelseledamot | 2015-09-01 |
| SQZ BIOTECHNOLOGIES COMPANY | Direktör/Styrelseledamot | 2021-07-01 |
| ARCH BIOPARTNERS INC. | Ordförande | 2026-01-15 |
| AVACTA GROUP PLC | Direktör/Styrelseledamot | 2026-07-06 |
F2G Ltd.
 F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Ordförande | 2019-04-08 |
Essential Pharmaceuticals LLC
 Essential Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Ordförande | - |
F2g Inc.
 F2g Inc. Miscellaneous Commercial ServicesCommercial Services F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape. | Direktör/Styrelseledamot | - |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Privat kapitalinvesterare | - |
Gyrus Capital SA
 Gyrus Capital SA Investment ManagersFinance Acts as an alternative investment manager | Privat kapitalinvesterare | 2020-06-25 |
| ░░░░░░░░░ ░░ | ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░ | ░░░░░░░░░░░ | - |
Tidigare kända positioner av Patrick Volkert Vink
| Företag | Position | Slut |
|---|---|---|
| ░░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░ ░░░ | ░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░░░ | ░░░░░░░░░░ |
Patrick Volkert Vinks utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
51
Första gradens relationer
30
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 30 |
|---|---|
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes generic pharmaceutical products | Health Technology |
Mylan, Inc.
 Mylan, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures generic pharmaceuticals | Health Technology |
Micreos BV
 Micreos BV Pharmaceuticals: MajorHealth Technology Operates as a biotech platform company that develops recombinant proteins for chronic dermatology conditions | Health Technology |
SQZ Biotechnologies Co.
 SQZ Biotechnologies Co. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops cell therapies for patients with cancer, infectious diseases and serious conditions | Health Technology |
Santhera Pharmaceuticals Holding AG
 Santhera Pharmaceuticals Holding AG Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for the treatment of neuromuscular diseases | Health Technology |
University of Leiden
 University of Leiden Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Avacta Group Plc
 Avacta Group Plc Miscellaneous Commercial ServicesCommercial Services Engages in the business of healthcare technology and consumables | Commercial Services |
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion is an active manager invest companies located in Northwest Europe and the United States. The firm focuses on companies operating in the fields of life sciences and biomedical technology. It participates in early stage capital requirements with an investment size ranging from EUR 1 - 7 million. It participates in follow-on investments, takes a board seat and acts as lead investor. | Finance |
F2G Ltd.
F2G Ltd. Pharmaceuticals: MajorHealth Technology Engages in research and development of novel drugs for life-threatening systemic fungal diseases treatment | Health Technology |
Sanofi-Synthelabo, Inc. | Health Technology |
Acacia Pharma Ltd.
 Acacia Pharma Ltd. Pharmaceuticals: MajorHealth Technology Provides supportive care product opportunities for post-surgical and cancer patients | Health Technology |
BiognoSYS AG
 BiognoSYS AG Packaged SoftwareTechnology Services Provides software and data platforms for life science researchers, biomarkers and drug developers | Technology Services |
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Focuses on the development and commercialization of targeted cancer immunotherapy | Health Technology |
Arch Biopartners, Inc.
 Arch Biopartners, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company which develops novel drugs | Health Technology |
Inhibikase Therapeutics, Inc.
 Inhibikase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes small-molecule kinase inhibitor therapeutics for neurological diseases | Health Technology |
Circio Holding ASA
 Circio Holding ASA BiotechnologyHealth Technology Develops active immunotherapy cancer vaccines | Health Technology |
Spero Therapeutics, Inc.
 Spero Therapeutics, Inc. BiotechnologyHealth Technology Develops therapies for the treatment of bacterial infections | Health Technology |
Advanz Pharma Corp. Ltd.
 Advanz Pharma Corp. Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
PIQUR Therapeutics AG
 PIQUR Therapeutics AG Pharmaceuticals: MajorHealth Technology Engages in discovery and development of anti-cancer drugs | Health Technology |
Acacia Pharma Group Ltd.
 Acacia Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company that engages in developing and commercializing novel products for surgery, invasive procedures & chemotherapy | Health Technology |
Amryt Pharma Holdings Ltd.
 Amryt Pharma Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals for patients with rare and orphan diseases | Health Technology |
NMD Pharma A/S
 NMD Pharma A/S BiotechnologyHealth Technology Discovers and develops novel therapeutics for neuromuscular diseases | Health Technology |
Essential Pharmaceuticals LLC
Essential Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products | Health Technology |
Essential Pharmaceuticals Ltd.
 Essential Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
Gyrus Capital SA
Gyrus Capital SA Investment ManagersFinance Acts as an alternative investment manager | Finance |
Secura Bio, Inc.
 Secura Bio, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products for oncology therapies | Health Technology |
Amryt Pharma Plc
 Amryt Pharma Plc Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company and develops and commercializing treatments for patients with rare & orphan diseases | Health Technology |
F2g Inc.
F2g Inc. Miscellaneous Commercial ServicesCommercial Services F2g Inc. is a biopharmaceutical and biotechnology company specializing in the discovery and development of novel antifungal therapies targeting rare, life-threatening fungal infections. The company is based in Princeton, NJ. The company leverages proprietary genomic and molecular biology technologies to develop small-molecule inhibitors, such as orotomides, which selectively inhibit fungal dihydroorotate dehydrogenase (dhodh), a key enzyme essential for fungal DNA, RNA, and protein synthesis. This mechanism induces fungal cell death and differs from existing antifungals that primarily inhibit fungal growth. The company's lead drug candidate, olorofim, targets invasive fungal infections such as invasive aspergillosis and coccidioidomycosis (valley fever), addressing unmet medical needs related to antifungal resistance, immunosuppressant use, and climate change. F2g’s pipeline includes oral and other formulations for rare, highly resistant mold infections affecting immunocompromised patients. The company offers an early access program for investigational therapies and maintains transparency through media updates, investor communications, and detailed information on its leadership, governance, scientific research, and the fungal disease landscape. | Commercial Services |
